Intra-peritoneal injection of LPS triggers intestinal pathology, including increased intestinal permeability and enteric alpha-synuclein accumulation, before the onset of brain pathology in rodent models of PD [88, 130]. This evidence concerns the gene SNCA and Parkinson disease.